By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Animal biotechnology firm MetaMorphix today announced the sale of its assets as part of its Chapter 11 bankruptcy filing.

The sale is for both its businesses, one directed at animal genomics, the other at growth and differentiation factors. American MedTech Advisors is advising the Calverton, MD.-based firm on the sale.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.